Vanguard Capital Management
FULC icon

Vanguard Capital Management’s Fulcrum Therapeutics FULC Stock Holding History

Vanguard Capital Management’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.87M Buy
2,697,216
+4,268
+0.2% +$26K ﹤0.01% 2826
2026
Q1 		$20.7M Buy
+2,692,948
New +$25M ﹤0.01% 2328

Other funds holding FULC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3B AUM 119.43% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Vanguard Capital Management's FULC Position: Q2 2026 in Review

Vanguard Capital Management increased its Fulcrum Therapeutics (FULC) stake by 0.16% in Q2 2026, buying an estimated $26K and bringing the position to 2,697,216 shares worth $9.87M. The position accounts for ﹤0.01% of the portfolio, ranked #2826.

Vanguard Capital Management first reported a position in FULC in Q1 2026 and has held it in 2 quarters since. The position peaked at $20.7M in Q1 2026. 154 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

  • Vanguard Capital Management held 2,697,216 shares of Fulcrum Therapeutics worth $9.87M as of Q2 2026.
  • Vanguard Capital Management bought 4,268 Fulcrum Therapeutics shares in Q2 2026, an estimated $26K.
  • Fulcrum Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2826 holding.
  • Vanguard Capital Management first reported a position in Fulcrum Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's Fulcrum Therapeutics position peaked at $20.7M in Q1 2026.
  • 154 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.